Page 110 - Fertility in Women with Rheumatoid Arthritis Vruchtbaarheid van vrouwen met reumatoïde artritis

Chapter 7
Table 1 – Characteristics of women with rheumatoid arthritis who participated in the PARA study and had a follow-up assessment in 2015/2016 (N=128)
Variables
Age (years)
at rst visit
at follow-up
Age at menarche (years) missing
Smokers at rst visit missing
Disease characteristics
Duration of disease (years)
at rst visit
at follow-up
Missing Presence of ACPA, n (%)
Presence of RF, n (%) Presence of erosions, n (%) missing
Hormone use at follow-up
None
Oral contraceptive pill Levonorgestrel releasing IUD Injectable progesterone
missing
31.8 ± 3.8 42.6 ± 4.4
13.1 ± 1.4 9 (7.0%)
9 (7.0%) 2 (1.6%)
4.8 (2.1-10.4) 15.8 (12.7-21.5) 1 (0.8%)
78 (61%)
85 (66%) 77 (60%) 3 (2.3%)
62 (48%) 25 (20%) 37 (29%) 2 (1.6%) 2 (1.6%)
Variables
Anti-rheumatic drugs at follow-up
Methotrexate Prednisone Sulfasalazine Hydroxychloroquine Leflunomide
Biologicals - total n (%) Etanercept
Infliximab Certolizumab Adalimumab Golimumab Abatacept Rituximab Tocilizumab
Use of methotrexate
Ever used MTX
missing Cumulative duration of MTX use
never used less than 1 year 1 to 5 years
5 to 10 years
> 10 years missing
Cumulative years MTX in users
65 (51%) 16 (13%) 15 (12%) 17 (13%) 5 (3.9%)
71 (55%) 29 (23%) -
2 (1.6%) 20 (16%) 3 (2.3%) 6 (4.7%) 2 (1.6%) 9 (7.0%)
113 (88%) 2 (1.6%)
13 (10%)
12 (9.3%)
27 (21%)
31 (24%)
25 (20%)
20 (16%)
5.8 (2.2-10.2)
RA = rheumatoid arthritis ; ACPA = anti-citrullinated protein antibodies ; RF = rheumatoid factor ; IUD = intra-uterine device ; MTX = methotrexate
We compared the 128 study participants to the non-participating subjects (n=167) of the former PARA cohort (Table 2). There was a signi cant lower percentage of smokers among participants (7%) than in the non-participants (17%) (p=0.013). Furthermore, nulliparity was signi cantly more common among the non-participants (22%) than in the participants (4.7%) at the end of their nal PARA episode (p<0.001). There were no signi cant differences in age, number of episodes participated in the PARA study, disease duration during the PARA study or current disease duration, presence of ACPA or RF, preconceptional disease activity during last PARA episode, or disease activity at the last PARA visit (either preconceptional or 6 months postpartum).
108